Clinical and Prognostic Significance of Lupus Anticoagulant Measurement in Patients With Lung Cancer

Fei, Xianming; Wang, Huan; Jiang, Lei; Zhao, Tao; Cheng, Maoliang; Yuan, Wufeng

doi:10.1177/1533034617714150

Cited by 5 publications

(10 citation statements)

References 25 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26,27] Fbg levels are also associated with advanced tumor metastasis. [18,22,28–30] The relationship between SCCA and Fbg was accorded with ULR in our study, and the higher the SCCA concentration was, the higher the Fbg levels were.…”

Section: Discussionsupporting

confidence: 79%

The relationship of plasma fibrinogen with clinicopathological stages and tumor markers in patients with non-small cell lung cancer

Bian¹,

Shi

Qi³

et al. 2019

Medicine

View full text Add to dashboard Cite

Numerous studies have shown that the blood of cancer patients are generally in hypercoagulable statement. The aim of the present research is to study the relationships of plasma fibrinogen (Fbg) levels with clinicopathological stages (CS) and tumor markers of non-small cell lung cancer (NSCLC). Baseline information, plasma Fbg levels, CS, and expression level of tumor markers were collected from medical records retrospectively. Unitary linear regression was used to analyze the relationships between continuous variables and Fbg, and multiple linear regression was used to analyze the relationships between categorical variables and Fbg. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (Version 4) for NSCLC were adopted to evaluate CS. A total of 652 NSCLC patients were included. Compared with the females, male patients had higher mean plasma Fbg levels ( P < .001). The later the N stages ( P = .002), M stages ( P = .002), and CS ( P = .001) were, the higher the average plasma Fbg levels were. The levels of squamous cell carcinoma antigen ( P = .001), carbohydrate antigen 125 ( P = .041), and neuron-specific enolase ( P < .001) were positively correlated with plasma Fbg concentration. The plasma level of Fbg in lung adenocarcinoma patients ( P < .001) was the lowest, while that of lung squamous cell carcinoma patients ( P < .001) was the highest in NSCLC patients. The plasma Fbg concentration is related to gender, CS, and tumor markers in patients with NSCLC.

show abstract

Section: Discussionsupporting

confidence: 79%

The relationship of plasma fibrinogen with clinicopathological stages and tumor markers in patients with non-small cell lung cancer

Bian¹,

Shi

Qi³

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…The three large-scale studies with VTE-related deaths reported rates ranging from 0.7-3.3% (27)(28)(29) whereas one small-scale prospective cohort study of newly diagnosed NSCLC patients reported a 4.2% VTE-related mortality rate (39). Three large-scale studies reported all-cause mortality rates from 7.5 to 63.9% (26,28,31) while the rates reported by three small-scale studies were from 9.7 to 78.3% (25,35,41).…”

Section: Rates Of Vte In Cancer Patientsmentioning

confidence: 95%

Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review

Lee

Nagarajan

Tan

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The epidemiology of cancer associated thrombosis (CAT) in Asia is less well-studied and differs from that in the western countries. Here, we systematically examine population based and hospital-based studies reported between 1995 and 2020 to understand the epidemiology of CAT in Asia. From population-based studies, the estimated incidence of VTE in cancer patients was 1.85–9.88 per 1,000 person-years. The incidence of CAT in Asia is significantly higher than non-cancer associated VTE in the general population and cancer is perhaps the most important risk factor for VTE. Hospital-based studies were heterogeneous in study designs and reveal a wide range of prevalence of VTE among cancer patients at 0.5–44.6% while the cancer prevalence rates among VTE patients ranged from 6.1 to 65.5%. The cancer sites most associated with VTE and risk factors were similar between Asian and Western studies. CAT has a major impact on the survival of patients with cancer in Asia, but thromboprophylaxis is not commonly practiced and validated risk assessment tools are lacking. This study highlights the urgent need for large multinational epidemiological studies in Asia to establish the true burden of CAT and to guide appropriate prevention strategies.

show abstract

“…Additionally, VTE can increase the risk rate of hemorrhage in cancer patients, thus delaying or interrupting chemotherapy, resulting in an inferior quality of life in patients (1,(4)(5)(6). Thrombus formation induces non-cancer causes of death in cancer patients and leads to a low survival rate (7). Therefore, early detection of VTE and reasonable anticoagulant therapy have a critical impact on the prognosis of cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer

Chen¹,

Li²,

Li³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

Background: Tumor-related coagulation dysfunction has been reported to be closely associated with poor prognosis. The present study is aimed to evaluate the prognostic prediction of an elevated plasma D-dimer cut-off value in advanced non-small cell lung cancer (NSCLC).Methods: A total of 233 patients initially diagnosed with advanced NSCLC were retrospectively analyzed, an elevated plasma cut-off value 981 ng/mL of D-dimer, which was instead of the clinical cut-off value 500 mg/mL, was used to determine the high and low. Univariate analysis using the Kaplan-Meier method and log-ranking test, and the multivariate analysis using the Cox proportional hazard regression model were performed.Results: Results showed when using the D-dimer value of 500 ng/mL as an evaluation standard, there was no significant difference in gender, age, smoking status, histopathology and overall survival rate between normal D-dimer (≤500 ng/mL) and high D-dimer (>500 ng/mL) group. However, when the evaluation standard for plasma D-dimer was set at 981 ng/mL, the age distribution of the high D-dimer (>981 ng/mL) group was significantly different from the normal D-dimer (≤981 ng/mL) group. Moreover, the overall survival rate in the high D-dimer (>981 ng/mL) group was significantly lower than that in the normal D-dimer (≤981 ng/mL) group. Conclusions:The present study implied that increasing the plasma D-dimer cut-off value to 981 ng/mL is more beneficial to prognosis prediction in advanced NSCLC.

show abstract

Clinical and Prognostic Significance of Lupus Anticoagulant Measurement in Patients With Lung Cancer

Cited by 5 publications

References 25 publications

The relationship of plasma fibrinogen with clinicopathological stages and tumor markers in patients with non-small cell lung cancer

The relationship of plasma fibrinogen with clinicopathological stages and tumor markers in patients with non-small cell lung cancer

Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review

Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer

Contact Info

Product

Resources

About